How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comA Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Description:
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Sponsor:
Memorial Sloan Kettering Cancer Center
Phase:
Phase 1
Contacts:
Alexander Shoushtari, MD (CONTACT)shoushta@mskcc.org
646-888-4161
Adam Schoenfeld, MD (CONTACT)schoenfa@mskcc.org
646-608-4042
Adam Schoenfeld, MD (PRINCIPAL_INVESTIGATOR)Government Study Link:
NCT06863233 - Click here to see study onClinicalTrials.gov
crefmirlimab berdoxam
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
- CD8 Cells
Ligand Class: Small Proteins and Antibody Fragments
Chelator: DFO
Inclusion
- Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
- Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
Exclusion
- Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)
Share your feedback
Help us improve your experience